NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 168 filers reported holding NEKTAR THERAPEUTICS in Q3 2015. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $182,000 | -17.3% | 10,200 | 0.0% | 0.01% | -16.7% |
| Q4 2019 | $220,000 | +18.3% | 10,200 | 0.0% | 0.01% | +20.0% |
| Q3 2019 | $186,000 | -48.8% | 10,200 | 0.0% | 0.01% | -54.5% |
| Q2 2019 | $363,000 | +5.8% | 10,200 | 0.0% | 0.01% | 0.0% |
| Q1 2019 | $343,000 | +2.4% | 10,200 | 0.0% | 0.01% | -15.4% |
| Q4 2018 | $335,000 | -46.1% | 10,200 | 0.0% | 0.01% | -38.1% |
| Q3 2018 | $622,000 | +24.9% | 10,200 | 0.0% | 0.02% | +10.5% |
| Q2 2018 | $498,000 | -69.8% | 10,200 | -34.2% | 0.02% | -71.6% |
| Q1 2018 | $1,647,000 | +74.5% | 15,500 | -1.9% | 0.07% | +76.3% |
| Q4 2017 | $944,000 | +121.1% | 15,800 | -11.2% | 0.04% | +100.0% |
| Q3 2017 | $427,000 | +22.7% | 17,800 | 0.0% | 0.02% | +18.8% |
| Q2 2017 | $348,000 | -16.7% | 17,800 | 0.0% | 0.02% | -15.8% |
| Q1 2017 | $418,000 | +91.7% | 17,800 | 0.0% | 0.02% | +72.7% |
| Q4 2016 | $218,000 | -19.6% | 17,800 | +12.7% | 0.01% | -21.4% |
| Q3 2016 | $271,000 | +7.1% | 15,800 | -11.2% | 0.01% | 0.0% |
| Q2 2016 | $253,000 | +7.7% | 17,800 | +4.1% | 0.01% | 0.0% |
| Q1 2016 | $235,000 | 0.0% | 17,100 | 0.0% | 0.01% | -6.7% |
| Q4 2015 | $235,000 | +25.7% | 17,100 | 0.0% | 0.02% | +25.0% |
| Q3 2015 | $187,000 | -1.1% | 17,100 | +13.2% | 0.01% | 0.0% |
| Q2 2015 | $189,000 | +13.9% | 15,100 | 0.0% | 0.01% | +9.1% |
| Q1 2015 | $166,000 | -29.1% | 15,100 | 0.0% | 0.01% | -26.7% |
| Q4 2014 | $234,000 | +28.6% | 15,100 | 0.0% | 0.02% | +15.4% |
| Q3 2014 | $182,000 | -6.2% | 15,100 | 0.0% | 0.01% | -7.1% |
| Q2 2014 | $194,000 | +6.0% | 15,100 | 0.0% | 0.01% | -6.7% |
| Q1 2014 | $183,000 | +7.0% | 15,100 | 0.0% | 0.02% | -11.8% |
| Q4 2013 | $171,000 | +51.3% | 15,100 | +39.8% | 0.02% | +30.8% |
| Q3 2013 | $113,000 | -9.6% | 10,800 | 0.0% | 0.01% | -23.5% |
| Q2 2013 | $125,000 | – | 10,800 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |